Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?

Moss, Esther L.; Evans, Tim; Pearmain, Philippa; Askew, Sarah; Singh, Kavita; Chan, Kiong K.; Ganesan, Raji; Hirschowitz, Lynn

doi:10.1097/igc.0000000000000477

Cited by 14 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Type II ovarian carcinomas account for most tubal and peritoneal cancers and seem to behave as one disease entity (25). In the peritoneum, metaplasia of presumed pluripotent stem cells has been linked to the promotion of synchronous malignant transformation at multiply foci, which in turn leads to peritoneal carcinomatosis (26).…”

Section: Introductionmentioning

confidence: 99%

Epithelial-to-Mesenchymal Transition in the Female Reproductive Tract: From Normal Functioning to Disease Pathology

et al. 2017

View full text Add to dashboard Cite

Epithelial-to-mesenchymal transition (EMT) is a physiological process that is vital throughout the human lifespan. In addition to contributing to the development of various tissues within the growing embryo, EMT is also responsible for wound healing and tissue regeneration later in adulthood. In this review, we highlight the importance of EMT in the development and normal functioning of the female reproductive organs (the ovaries and the uterus) and describe how dysregulation of EMT can lead to pathological conditions, such as endometriosis, adenomyosis, and carcinogenesis. We also summarize the current literature relating to EMT in the context of ovarian and endometrial carcinomas, with a particular focus on how molecular mechanisms and the tumor microenvironment can govern cancer cell plasticity, therapy resistance, and metastasis.

show abstract

Section: Introductionmentioning

confidence: 99%

Epithelial-to-Mesenchymal Transition in the Female Reproductive Tract: From Normal Functioning to Disease Pathology

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Further, the levels of epithelial ovarian cancer markers HE4 and CA125 are usually below normal reference limits in AGCT patients. As the knowledge on the origins of ovarian cancer has increased [30,31], we nowadays appreciate that the different ovarian cancer subtypes have divergent diagnostic paths and expression levels of circulating tumor markers [32,33]. The differential diagnostics delineates the referral of patients with suspected ovarian cancer to specialized centers, which is associated with significantly improved survival, underlining the value of accurate preoperative diagnostics [1,2].…”

Section: Discussionmentioning

confidence: 99%

Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Müllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors

Haltia

Hallamaa

Tapper

et al. 2017

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

“…Low grade serous, mucinous, endometrioid, and clear cell carcinomas fall within the Type I classification [ 5 ]. These tumors arise from endometrial tissue, fallopian tube tissue, germ cells, and transitional epithelium [ 5 , 14 , 15 , 18 , 21 , 22 ]. Type I tumors grow more slowly (are indolent) and are considered to be more genetically stable [ 5 , 14 , 20 ].…”

Section: Histologic Types Of Ovarian Cancermentioning

confidence: 99%

Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer?

Roy

Dahl

2018

Cancers

View full text Add to dashboard Cite

Ovarian cancer is the most lethal gynecological malignancy. Poor overall survival, particularly for patients with high grade serous (HGS) ovarian cancer, is often attributed to late stage at diagnosis and relapse following chemotherapy. HGS ovarian cancer is a heterogenous disease in that few genes are consistently mutated between patients. Additionally, HGS ovarian cancer is characterized by high genomic instability. For these reasons, personalized approaches may be necessary for effective treatment and cure. Understanding the molecular mechanisms that contribute to tumor metastasis and chemoresistance are essential to improve survival rates. One favored model for tumor metastasis and chemoresistance is the cancer stem cell (CSC) model. CSCs are cells with enhanced self-renewal properties that are enriched following chemotherapy. Elimination of this cell population is thought to be a mechanism to increase therapeutic response. Therefore, accurate identification of stem cell populations that are most clinically relevant is necessary. While many CSC identifiers (ALDH, OCT4, CD133, and side population) have been established, it is still not clear which population(s) will be most beneficial to target in patients. Therefore, there is a critical need to characterize CSCs with reliable markers and find their weaknesses that will make the CSCs amenable to therapy. Many signaling pathways are implicated for their roles in CSC initiation and maintenance. Therapeutically targeting pathways needed for CSC initiation or maintenance may be an effective way of treating HGS ovarian cancer patients. In conclusion, the prognosis for HGS ovarian cancer may be improved by combining CSC phenotyping with targeted therapies for pathways involved in CSC maintenance.

show abstract

Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?

Cited by 14 publications

References 32 publications

Epithelial-to-Mesenchymal Transition in the Female Reproductive Tract: From Normal Functioning to Disease Pathology

Epithelial-to-Mesenchymal Transition in the Female Reproductive Tract: From Normal Functioning to Disease Pathology

Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Müllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors

Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer?

Contact Info

Product

Resources

About